A report reveals a 146 percent surge in female testosterone prescriptions, but experts warn the evidence strictly limits its use to sexual desire disorders.
On September 15, 2026, Reuters reported a 146 percent increase in the rate of women receiving testosterone prescriptions between January 2023 and July 2026 based on Truveta healthcare analytics data. The report highlighted expert warnings that current evidence does not support using the hormone to improve muscle mass, bone density, or mood.
Previously, testosterone use in women was largely confined to specialized clinical conversations about specific sexual desire disorders. The standard of care for midlife women centered on managing prominent symptoms with established therapies without positioning the hormone as a mainstream option for general aging concerns. Medical practitioners focused on localized or systemic estrogen and progesterone to manage physical changes. The idea of prescribing a controlled substance for muscle building simply did not factor into conventional female hormone care.
The Reuters report described the prescribing rate as nearly tripling over a three-year period. This rapid growth is happening alongside wider public interest in menopausal hormone therapy. Women are paying closer attention to their changing bodies and seeking answers for shifting energy levels. Many are looking for comprehensive perimenopause, menopause and hormonal change articles that explain these complex physical transitions.
The Truveta analysis provided a stark percentage, but the underlying methodology remains narrow. Reuters noted that the figures measure the rate of women receiving a prescription. The news outlet did not publish the full patient count, prescription count, or statistical methodology used by the analytics firm. The data acts as a clear signal of rising prescription activity rather than a complete picture of nationwide hormone use.
This surge in demand reflects a growing desire for proactive medical care among midlife women. However, rising prescription numbers do not mean the therapy is universally effective for the reasons women are seeking it. The 146 percent increase should be read as a shift in clinical behavior. It is not proof that the hormone has suddenly been proven to improve a woman's strength or metabolism.
The recent coverage maps out a complex landscape of rising demand colliding with strict clinical boundaries. The core findings identify significant safety and regulatory gaps.
Social media frequently positions the hormone as a modern shortcut for building muscle and losing fat. Medical authorities maintain a much more restricted view based on clinical data. Paloma Health summarized the Global Consensus Position Statement on the matter. That consensus identifies hypoactive sexual desire disorder in postmenopausal women as the only evidence-based indication.
Hypoactive sexual desire disorder involves persistent and distressing low desire that requires a thorough clinical assessment. It is not simply a passing phase or a minor symptom of aging. A careful clinician will separate this condition from normal shifts in desire, sleep disruption, or medication effects. Women reading sexual wellbeing and intimate confidence articles often find practical frameworks for understanding these complex physical layers.
The consensus firmly states that current evidence remains insufficient for treating energy, mood, weight, and general well-being.
Dr. Stephanie Faubion, director of the Mayo Clinic Center for Women's Health and medical director of The Menopause Society, addressed the marketing directly. "We do not have any evidence in women that it will improve muscle mass or bone density or mood or well-being or really any other metric," she told Reuters. She noted that what the hormone is being promoted for publicly is not what the data actually supports.
Testosterone levels alone do not constitute a diagnosis that requires automatic treatment. True evidence-supported care focuses on an assessed sexual health disorder rather than a blanket attempt to optimize hormone levels.
The lack of an approved female product creates significant logistical barriers for women who receive a prescription. The access problem stems largely from safety and compliance concerns rather than proof that the hormone itself is entirely ineffective. Pharmacist Kevin Schipper of ProPharma explained to Reuters that pharmacies worry about dosing accuracy, product stability, and contamination risks. These specific issues arise when a patient is instructed to split a single-use package over several days.
These concerns translate into real-world delays and denials at the pharmacy counter. Amazon Pharmacy told Reuters it does not dispense some prescriptions that require patients to customize doses. The company cited safe and compliant dispensing policies. It confirmed that it refers these customers to compounding pharmacies for specialized doses.
Jennifer Lanoff, a women's health nurse practitioner in Washington, D.C., observed Amazon Pharmacy rejecting prescriptions from her practice for the first time in 2026. She described the sudden rejection issue as resulting from a new pharmacy policy. Magen Price, founder of Mystic Valley Sexual Wellness, noted similar hurdles in her own practice. She stated that more than one-third of her 80 patients using the hormone had encountered prescription problems.
Price cited specific issues at major retail chains like CVS and Walgreens. CVS told Reuters its pharmacies regularly fill prescriptions for topical testosterone gel for women. Walgreens, Costco, and Walmart did not respond to requests for comment from Reuters, and Kroger declined to comment.
The resulting friction costs patients valuable time and energy. One patient, Amy Swan, told Reuters she spent weeks trying to fill her first gel prescription in March 2026. She reported losing hours simply dealing with the prescription logistics.
Insurance policies create another significant hurdle for midlife women seeking treatment. Reuters found that most insurance companies do not cover testosterone for women. The news report did not identify specific insurers or provide a systematic coverage analysis. Doctors, nurses, and patients consistently reported broad coverage denials during interviews.
This lack of coverage forces many patients to pay out of pocket or seek alternative compounding routes. Compounded medications offer customized dosing, but they can carry higher costs. Lanoff estimated that compounded testosterone costs about $100 for a three-month supply. A discounted commercial supply might cost roughly $30 for a 10-month duration.
Compounding pharmacies can solve the dose division problem, but they are not universally more affordable. The absence of an FDA-evaluated product specifically for women limits confident prescribing. Cynthia Stuenkel is a clinical professor of medicine at the University of California, San Diego. She noted that a dedicated product could make prescribing much more confident for clinicians. She added that a formally evaluated product could make patient use much more reliable.
The FDA scheduled a public workshop for September 17, 2026, to review the existing evidence concerning testosterone use in menopausal women. The agency maintains that off-label uses of approved medicines have not been evaluated for safety, efficacy, or dosing.
The pharmaceutical industry recognizes the regulatory gap and is taking steps to address it. Reuters reported that more than 30 clinical trials examining testosterone for various health conditions in women were underway or planned. The existence of these trials indicates strong ongoing research interest. Planned or ongoing trials are not evidence of positive outcomes.
Specific companies are currently testing new medical formulations. Marius Pharmaceuticals sponsored a sexual dysfunction trial expected to begin as soon as later in 2026. Aviva Bio is developing a next-generation product intended to address the breast cancer risk associated with testosterone use.
Until these clinical trials conclude and the FDA approves a specific formulation, patients and providers must navigate a highly restricted landscape. Women should ask their clinicians clear questions about the expected benefits, monitoring requirements, and possible adverse effects before starting any off-label treatment. Clear instructions on how to measure doses accurately and store the product safely are absolutely critical. Pharmacists continue to highlight these exact variables as major safety concerns.
Women navigating the physical shifts of midlife often seek clarity on what is purely hormonal and what has multiple physiological causes. Treating every sign of aging as a hormone deficiency can distract from proven, reliable lifestyle interventions. Building a sustainable health strategy requires an honest look at daily habits rather than relying on a single prescription to solve every concern.
If your primary goal is building strength and changing your body composition, the clinical evidence does not support using testosterone as a performance intervention. Medical guidance advises clinicians to look closely at the many variables affecting a woman's metabolism, muscle mass, and daily energy levels. Solid nutrition and weight management articles focus on meeting protein needs, managing blood sugar, and supporting muscle recovery through food.
Nutrition, sleep quality, and progressive resistance training play much larger, proven roles in preserving physical capability through the transition. The most defensible conclusion is not that this hormone is never appropriate for any midlife woman. The clinical reality is simply that the therapy has a very narrow evidence base restricted to a specific clinical diagnosis.
Testosterone is an option for appropriately assessed postmenopausal women with distressing low sexual desire. It is not an everyday supplement, a simple mood lifter, or an effortless way to reclaim lost muscle mass.
Going forward, clinical practice must rigidly separate evidence-supported sexual health treatments from unsubstantiated metabolic optimization while researchers track outcomes across the 30 planned clinical trials.
Sorting through hormone prescriptions and unverified anti-aging claims often falls to the individual woman acting as her own health advocate, but the landscape changes when Refemina provides the underlying evidence. We counter health content that treats every problem as a supplement, hormone or weight-loss opportunity, helping you navigate perimenopause and body composition changes with clear adult guidance. Explore Resources
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources